IOVA vs TARS: stock comparison and AI forecast
Iovance Biotherapeutics, Inc. (IOVA) and Tarsus Pharmaceuticals, Inc. (TARS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
IOVA Iovance Biotherapeutics, Inc.
- Market Cap
- $3.51B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
TARS Tarsus Pharmaceuticals, Inc.
- Price
- $67.52 +4.3% · 6M
- Market Cap
- $3.33B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- IOVA and TARS have similar market capitalizations ($3.51B and $3.33B).
- IOVA turns -58.2% of its revenue into net income, against -102.9% for TARS.
- TARS carries 3.86 times debt per unit of equity, against 0.22 times for IOVA.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | IOVA | TARS |
|---|---|---|
| Market Cap | $3.51B | $3.33B |
| P/B Ratio | 4.31x | 32.01x |
| EPS | $-0.81 | $-15.64 |
| Book Value/Share | $1.79 | $2.11 |
| Revenue/Share | $0.84 | $13.83 |
| FCF/Share | $-0.48 | $0.66 |
Profitability & Margins
| Metric | IOVA | TARS |
|---|---|---|
| ROE | -27.1% | -675.0% |
| ROA | -22.2% | -138.9% |
| ROIC | -26.0% | – |
| Gross Margin | 57.1% | – |
| Operating Margin | -60.8% | -102.0% |
| Net Margin | -58.2% | -102.9% |
| EBT Margin | -58.5% | -97.2% |
| Tax Rate | 0.6% | -1.8% |
Financial Health
| Metric | IOVA | TARS |
|---|---|---|
| Current Ratio | 5.20x | 1.96x |
| Quick Ratio | 4.67x | 1.94x |
| D/E Ratio | 0.22x | 3.86x |
| Financial Leverage | 1.22x | 4.86x |
| Interest Coverage | 31.2x | -303.0x |
| Working Capital | $444M | $218M |
Cash Flow
| Metric | IOVA | TARS |
|---|---|---|
| Operating Cash Flow | -$190M | $50M |
| Free Cash Flow | -$216M | $32M |
| Capital Spending | -$26M | -$17M |
| FCF/Sales | -57.0% | 4.8% |
| CapEx/Sales | 6.9% | 2.6% |
Operational Efficiency
| Metric | IOVA | TARS |
|---|---|---|
| Asset Turnover | 0.38x | 1.35x |
| Receivables Turnover | 3.5x | 6.8x |
| Inventory Turnover | 2.9x | – |
| Fixed Assets Turnover | 2.9x | 32.9x |
| Days Sales Outstanding | 103 days | 54 days |
| Days Inventory | 124 days | – |
| Payables Period | 49 days | – |
| Cash Conversion Cycle | 178 days | – |
Income Statement
| Metric | IOVA | TARS |
|---|---|---|
| Total Revenue | $379M | $682M |
| Operating Income | -$230M | -$696M |
| Net Income | -$221M | -$702M |
| R&D Expense | $240M | $116M |
| SG&A Expense | – | $586M |
| Cost of Goods Sold | $162M | – |
Dividend & Shareholder Information
| Metric | IOVA | TARS |
|---|---|---|
| Shares Outstanding | 453M | 49M |
IOVA vs TARS: stock comparison and AI forecast
Which is bigger, IOVA or TARS?
IOVA and TARS have similar market capitalizations ($3.51B and $3.33B).
Which one does Intratio's AI model rank higher, IOVA or TARS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.